{
    "root": "2fa02a6e-cd15-8b59-e063-6394a90ad9d1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "REMICADE",
    "value": "20250305",
    "ingredients": [
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T"
        },
        {
            "name": "INFLIXIMAB",
            "code": "B72HH48FLU"
        }
    ],
    "indications": "remicade tumor necrosis factor ( tnf ) blocker indicated : crohn 's disease : reducing signs symptoms inducing maintaining remission adult patients moderately severely active disease inadequate response conventional therapy . ( 1.1 ) reducing number draining enterocutaneous rectovaginal fistulas maintaining fistula closure adult patients fistulizing disease . ( 1.1 ) pediatric crohn 's disease : reducing signs symptoms inducing maintaining remission pediatric patients 6 years age older moderately severely active disease inadequate response conventional therapy . ( 1.2 ) ulcerative colitis : reducing signs symptoms , inducing maintaining remission mucosal healing , eliminating corticosteroid adult patients moderately severely active disease inadequate response conventional therapy . ( 1.3 ) pediatric ulcerative colitis : reducing signs symptoms inducing maintaining remission pediatric patients 6 years age older moderately severely active disease inadequate response conventional therapy . ( 1.4 ) rheumatoid arthritis combination methotrexate : reducing signs symptoms , inhibiting progression structural damage , improving physical function adult patients moderately severely active disease . ( 1.5 ) ankylosing spondylitis : reducing signs symptoms adult patients active disease . ( 1.6 ) psoriatic arthritis : reducing signs symptoms active arthritis , inhibiting progression structural damage , improving physical function adult patients . ( 1.7 ) plaque psoriasis : treatment adult patients chronic severe ( i.e . , extensive and/or disabling ) plaque psoriasis candidates systemic therapy systemic therapies medically less appropriate . ( 1.8 )",
    "contraindications": "prior treatment , ensure appropriate personnel medication available treat ( e.g . , hypersensitivity ) occur infusion shortly infusion . ( 2.11 ) remicade administered intravenous infusion least 2 hours in-line filter ( 2.11 ) crohn 's disease : 5 mg/kg 0 , 2 6 weeks , every 8 weeks . adult patients initially respond treatment may benefit increasing dose 10 mg/kg every 8 weeks later lose response . ( 2.1 ) pediatric crohn 's disease ( \u2265 6 years old ) : 5 mg/kg 0 , 2 6 weeks , every 8 weeks . ( 2.2 ) ulcerative colitis : 5 mg/kg 0 , 2 6 weeks , every 8 weeks . ( 2.3 ) pediatric ulcerative colitis ( \u2265 6 years old ) : 5 mg/kg 0 , 2 6 weeks , every 8 weeks . ( 2.4 ) rheumatoid arthritis : conjunction methotrexate , 3 mg/kg 0 , 2 6 weeks , every 8 weeks . patients may benefit increasing dose 10 mg/kg every 8 weeks treating often every 4 weeks . ( 2.5 ) ankylosing spondylitis : 5 mg/kg 0 , 2 6 weeks , every 6 weeks . ( 2.6 ) psoriatic arthritis plaque psoriasis : 5 mg/kg 0 , 2 6 weeks , every 8 weeks . ( 2.7 , 2.8 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "remicade doses > 5 mg/kg contraindicated patients moderate severe heart failure [ ( 5.5 ) ( 6.1 ) ] . remicade contraindicated patients previous severe hypersensitivity reaction infliximab inactive ingredients remicade murine proteins [ severe hypersensitivity included anaphylaxis , hypotension , serum sickness ] [ ( 5.7 ) ( 6.1 ) ] .",
    "indications_original": "REMICADE is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis : treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )",
    "contraindications_original": "Prior to treatment, ensure appropriate personnel and medication are available to treat reactions (e.g., hypersensitivity) that occur during infusion and shortly after infusion. ( 2.11 ) REMICADE is administered by intravenous infusion for at least 2 hours with an in-line filter ( 2.11 ) Crohn's Disease : 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some adult patients who initially respond to treatment may benefit from increasing the dose to 10 mg/kg every 8 weeks if they later lose their response. ( 2.1 ) Pediatric Crohn's Disease (\u2265 6 years old) : 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( 2.2 ) Ulcerative Colitis : 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( 2.3 ) Pediatric Ulcerative Colitis (\u2265 6 years old) : 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( 2.4 ) Rheumatoid Arthritis : In conjunction with methotrexate, 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. Some patients may benefit from increasing the dose up to 10 mg/kg every 8 weeks or treating as often as every 4 weeks. ( 2.5 ) Ankylosing Spondylitis : 5 mg/kg at 0, 2 and 6 weeks, then every 6 weeks. ( 2.6 ) Psoriatic Arthritis and Plaque Psoriasis : 5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks. ( 2.7 , 2.8 )",
    "adverseReactions_original": "The use of REMICADE at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure\n \n  [see\n  \n   Warnings and Precautions (5.5)and\n  \n   Adverse Reactions (6.1)]\n \n  .\n\n \n                  REMICADE is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab or any of the inactive ingredients of REMICADE or any murine proteins [severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness]\n \n  [see\n  \n   Warnings and Precautions (5.7)and\n  \n   Adverse Reactions (6.1)]."
}